Loading organizations...
§ Private Profile · Bristol, Bristol, United Kingdom
Cell & Gene Therapy CDMO providing consultancy, process development, and GMP manufacturing for viral vectors, cell therapies, and RNA.
eXmoor Pharma is a contract development and manufacturing organization specializing in cell and gene therapies, based in Bristol, United Kingdom. The company provides integrated consultancy, process development, and Good Manufacturing Practice (GMP) production services to help biotechnology and pharmaceutical firms advance viral vectors, cell therapies, and RNA technologies. Operating with approximately 80 employees and generating $16.9 million in annual revenue, the firm has successfully completed over 500 distinct projects for more than 170 global partners while maintaining a 70 percent repeat business rate. To support the expansion of its manufacturing capabilities under the leadership of Chief Executive Officer Lucy Foley, the organization secured $35 million in Series A venture capital funding backed by lead investors Kineticos Ventures and MVM Partners. eXmoor Pharma was originally founded in 2004 by Angela Osborne, Gavin Sutton, and Tim Nicholls.
eXmoor Pharma has raised $35.0M across 1 funding round.
eXmoor Pharma has raised $35.0M in total across 1 funding round.
eXmoor Pharma has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 30, 2023 | $35M Series A | Frank LIS, MVM Partners | — | Announced |
eXmoor Pharma has raised $35.0M in total across 1 funding round.
eXmoor Pharma's investors include Frank Lis, MVM Partners.